ライフサイエンスコーパス: lymphocyte count

1 s (despite typical decreases in platelet and lymphocyte counts).

2 s effect differs depending on CD4-positive T-lymphocyte count.

3 ng that coincided with normalization of CD3+ lymphocyte count.

4 ion and inversely correlates with the CD4(+) lymphocyte count.

5 ty, age group, sex, HIV/AIDS status, and CD4 lymphocyte count.

6 57% of all submitted samples showed a raised lymphocyte count.

7 B1 concentration is associated with absolute lymphocyte count.

8 lucose concentration and a decrease in blood lymphocyte count.

9 , and negatively associated with post-stroke lymphocyte counts.

10 easons may account for BL deficit at low CD4 lymphocyte counts.

11 ted with lower viral loads and higher CD4(+) lymphocyte counts.

12 ation of these changes with overall CD4(+) T lymphocyte counts.

13 but not to CD4 cell, total T cell, or total lymphocyte counts.

14 mycin resistance among patients with low CD4 lymphocyte counts.

15 undetectable viral loads and intact CD4(+) T-lymphocyte counts.

16 f GFP+ T cells showed normalization of their lymphocyte counts.

17 ngoing HIV replication but may increase CD4+ lymphocyte counts.

18 ntermittently based on peripheral blood CD3+ lymphocyte counts.

19 ociated with HIV RNA levels than with CD4(+) lymphocyte counts.

20 tgrowth patterns and inversely with CD4(+) T lymphocyte counts.

21 a HIV-1 viral load and increases in CD4(+) T-lymphocyte counts.

22 , and higher peak white blood cell (WBC) and lymphocyte counts.

23 across individuals were most correlated with lymphocyte counts.

24 x 1000 cells/muL [IQR, 5.6, 12.1]; P = .02), lymphocyte count (0.9 x 1000 cells/muL [IQR, 0.8, 1.1] v

25 .83 x 10(9) cells/L; P < 0.001), and similar lymphocyte counts (0.022 x 10(9) cells/L; P = 0.36), whe

26 0.11 x 10(9) cells/L; P = 0.026), and higher lymphocyte counts (0.095 x 10(9) cells/L; P < 0.001).

27 2%), and > or = 50% reduction in circulating lymphocyte counts (11 of 22 patients; 50%).

28 ts/mL; P < .001), higher cerebrospinal fluid lymphocyte counts (122 vs 8 cells/muL; P < .001), and a

29 ficant (P < .05) increases in their adjusted lymphocyte counts (+126 cells/mm(3); approximately +7%),

30 e blood cell count (17 [19%]), and decreased lymphocyte count (14 [15%]).

31 onic, untreated malaria, NMI monkeys had a B lymphocyte count 23 times greater than that of PMI monke

32 in 267 (15%) of 1748 patients (median CD4+ T-lymphocyte count, 242 per cubic millimeter; interquartil

33 ), dyspnoea (29 [6%] vs ten [2%]), decreased lymphocyte count (29 [6%] vs nine [2%]), diarrhoea (18 [

34 ontrol subjects (odds ratio adjusted for CD4 lymphocyte count, 3.8; 95% confidence interval, 2.2-6.5)

35 , (2) is associated with a rapid recovery of lymphocyte counts, (3) reverses cytokine activation defi

36 cidofovir; CR = 13 (80%) vs 8 (35%); median lymphocyte count = 320/mul vs 910/mul; P < .05).

37 94 study participants (median initial CD4(+) lymphocyte count, 518 lymphocytes/mm(3)), 90 (18%) progr

38 To do so, we conducted a GWAS for lymphocyte count, a physiologic quantitative trait assoc

39 circulating immature myeloid cells, absolute lymphocyte count above 2.5 x 10(9)/L, and marrow blasts

40 nt risk factors for mortality were low total lymphocyte count, advanced age, and male sex.

41 veries of absolute neutrophil, platelet, and lymphocyte counts after each TBI dose, responses to rcG-

42 was no change in circulating eosinophil and lymphocyte counts after stenting in the allergy group (0

43 atients had Rai stage 0 CLL with an absolute lymphocyte count (ALC) < or = 10 x 10(9)/L; and 219 pati

44 dose total body irradiation, and an absolute lymphocyte count (ALC) </=100/mm(3) at the time of URI o

45 a sustained > or = 20% reduction in absolute lymphocyte count (ALC) and 11 (92%) of 12 patients with

46 d SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes

47 Absolute lymphocyte count (ALC) is considered a surrogate marker

48 Absolute lymphocyte count (ALC) is considered a surrogate marker

49 We hypothesized that a lower absolute lymphocyte count (ALC) may alter HCV outcome after liver

50 antation have been related to early absolute lymphocyte count (ALC) recovery as a manifestation of ea

51 garding which lymphocyte parameter (absolute lymphocyte count [ALC] or B-cell count) and what thresho

52 on chemoprophylaxis, graft failure, absolute lymphocyte counts (ALCs), and mortalities were collected

53 Neither monocyte counts nor lymphocyte counts alone were associated with tuberculosi

54 Total lymphocyte count also predicted a subsequent CD4(+) T ce

55 loci of small effects influence variation in lymphocyte count and asthma susceptibility.

56 the immunologic parameters of blood CD4(+) T lymphocyte count and breadth of the HIV-1-specific CTL r

57 dy mass index, and (for those with HIV) CD4+ lymphocyte count and HIV RNA levels.

58 Cheaper, simpler alternatives to CD4 lymphocyte count and HIV-1 RNA detection for assessing t

59 -1 infection and correlated with both CD4(+) lymphocyte count and HIV-1 RNA level.

60 CD4(+) lymphocyte count and human immunodeficiency virus (HIV)

61 a more aggressive murine CLL as measured by lymphocyte count and inferior survival.

62 hese effects remained significant after CD4+ lymphocyte count and plasma HIV-1 RNA load at baseline w

63 -1 disease progression independently of CD4+ lymphocyte count and plasma HIV-1 RNA load, suggesting t

64 , there was a modest rebound in the absolute lymphocyte count and serum complement levels, but substa

65 one that replaced CD4 cell count with total lymphocyte count and severity of anaemia (total lymphocy

66 s demonstrated both early reduction in blood-lymphocyte count and spleen size and prolongation of sur

67 The mean+/-SEM CD4(+) T lymphocyte count and virus load for all patients were 23

68 had higher total white blood cell count and lymphocyte count and were further out from transplant co

69 st or current HGV infection have higher CD4+ lymphocyte counts and better AIDS-free survival rates.

70 d upper abdominal pain, as well as decreased lymphocyte counts and elevated liver aminotransferase le

71 of both conditions increases with lower CD4 lymphocyte counts and higher HIV-1 RNA levels.

72 antly associated with higher activated CD8 T lymphocyte counts and higher viral load levels.

73 s and WBC, absolute neutrophil, and absolute lymphocyte counts and increased prothrombin time and cre

74 anti-LTbetaR mAb significantly increased PP lymphocyte counts and intestinal IgA in PN fed-mice.

75 en and women, is associated with higher CD4+ lymphocyte counts and lower plasma HIV viral burdens, an

76 Serum CD4(+) T-lymphocyte counts and SIV copy numbers did not differ be

77 esponses, CD4 and CD8 T-cell count, absolute lymphocyte count), and other transplantation-related fac

78 Disease duration, lymphocyte count, and azathioprine use were shown to be

79 gue, maculopapular rash, dyspnoea, decreased lymphocyte count, and decreased neutrophil count (two [3

80 ger, injection drug use, lower baseline CD4+ lymphocyte count, and higher baseline viral load.

81 count, the percentage of white blood cells, lymphocyte count, and interleukin 2R were affected by co

82 e bone sarcoma group, and anaemia, decreased lymphocyte count, and prolonged activated partial thromb

83 type, HIV and HCV viral loads, CD4+ and CD8+ lymphocyte counts, and 12-year AIDS-free survival by HGV

84 hic variables, plasma HIV-1 RNA levels, CD4+ lymphocyte counts, and adverse drug reactions.

85 lower C3 levels, hemoglobin levels, absolute lymphocyte counts, and albumin levels, and a higher anti

86 age, HIV and HCV viral loads, CD4+ and CD8+ lymphocyte counts, and CCR5 genotype.

87 f these measures and current or nadir CD4+ T-lymphocyte counts, and each measure was compared between

88 , chronic underlying condition, low absolute lymphocyte counts, and elevated creatinine levels were a

89 Viral load, lymphocyte counts, and HIV-1-specific CD8(+) cell immune

90 linical, demographic, and exposure data, CD4 lymphocyte counts, and stool samples for detection of en

91 he plasma HIV-1 RNA level, CD4(+) and CD8(+) lymphocyte counts, and the CD8(+) cell anti-HIV response

92 time led to decreases in platelet count and lymphocyte counts, and to increases in MCV and monocytes

93 unosuppression as measured by viral load and lymphocyte count; and viral reactivation patterns differ

94 rkedly reduced lymphocyte homing and reduced lymphocyte counts as a result of significantly decreased

95 ed with the magnitude of the increase in CD4 lymphocyte count, as were haplotypes in genes encoding i

96 Median CD4 lymphocyte count at diagnosis of a new ADI increased fro

97 The median CD4(+) lymphocyte count at lymphoma diagnosis has decreased sig

98 ased with early infection, low maternal CD4+ lymphocyte count at recruitment, and frequent morbidity.

99 edian CD4+, CD8+, and CD19+ peripheral blood lymphocyte counts at 73-84 months after therapy were 185

100 Immunity was assessed by CD4 T-lymphocyte counts at AIDS onset.

101 the herpes event nor the patients' absolute lymphocyte counts at baseline differed significantly bet

102 ls </=0.15 or 0.16 to 0.56 mug/mL had higher lymphocyte counts at day +30 and higher T-cell counts at

103 ame CD4 count, whereas women have higher CD4 lymphocyte counts at the time of AIDS diagnosis.

104 undant thymic tissue had higher naive CD4+ T lymphocyte counts at weeks 2-24 after therapy than indiv

105 After controlling for age, baseline CD4(+) lymphocyte count, baseline HIV-1 RNA level, and durable

106 or relapse was associated with baseline CD4 lymphocyte count, being 12.3% (9/73; 95% confidence inte

107 mia coincided with recovery of normal CD8+ T lymphocyte counts between days 48 and 76.

108 rane thickness, and BAL fluid neutrophil and lymphocyte counts but not eosinophil counts.

109 atients with CLL, even with high circulating lymphocyte counts, but were frequent in patients with ot

110 1), total WBC count by 139% (P = 0.006), and lymphocyte count by 106% (P = 0.02).

111 a significant reduction in peripheral blood lymphocyte count by up to 85%, which reversed within 3 d

112 r non-Hodgkin lymphoma (NHL), by age and CD4 lymphocyte count categories, were estimated using Poisso

113 , OFA therapy rapidly decreased the absolute lymphocyte count, CD20 expression by CLL cells, and seru

114 -genome screen for quantitative variation in lymphocyte count, CD4 T cell, CD8 T cell, B cell, and na

115 Activated CD4(+)/CD25(+) T-lymphocyte counts correlated negatively with serum conce

116 of IP-10/CXCL10, whereas CD4(+)/HLA-DR(+) T lymphocyte counts correlated positively with serum conce

117 imited data exist regarding whether relative lymphocyte count correlates with postdischarge outcomes

118 At week 8, absolute lymphocyte counts declined 49% from baseline in the grou

119 trophil counts were elevated (4.8x), whereas lymphocyte counts declined.

120 Lymphocyte counts decreased with BG-12.

121 A CD4 T-lymphocyte count determines eligibility for antiretrovir

122 rphologic changes and CD3(+) intraepithelial lymphocyte counts differed significantly from baseline t

123 o were positive for HGV RNA, had higher CD4+ lymphocyte counts (difference, 211 cells/mm3 [95% Cl, 88

124 Low CD4+ T-lymphocyte count, disease stage, performance status, ser

125 CD8, CD3, and total lymphocyte counts dropped concomitantly.

126 Low relative lymphocyte count during hospitalization for HF is an ind

127 should be aware of their patients' absolute lymphocyte counts during peg-IFN/RBV therapy; peg-IFN do

128 Despite differences in eosinophil and lymphocyte counts during the first 24 hours posttreatmen

129 CD4(+) T lymphocyte counts, eosinophil counts, and plasma HIV-1 R

130 two (3%) for acute kidney injury, decreased lymphocyte count, fatigue, neutropenia, and sepsis, and

131 In the prospective cohort, lymphocyte counts fell 90 minutes after reperfusion, pri

132 e events were anaemia (six [14%]), decreased lymphocyte count (five [12%]), prolonged activated parti

133 rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of

134 those after direct intranasal infection, but lymphocyte counts from nasal washes diminished with tran

135 nt-naive or interferon-experienced, had CD4+ lymphocyte count >/=200 cells/microL or >/=14%, and plas

136 an HIV-1 RNA load <50 copies/mL and CD4(+) T lymphocyte count >400 cells/mm(3) were randomized to und

137 >20 000 cells/microL (aOR, 4.6), and to have lymphocyte counts >10 000 cells/microL (aOR, 7.2) (all P

138 ); (2) HIV-infected individuals whose CD4+ T-lymphocyte counts had always been more than 200/microL (

139 x [MAC] infection) in persons whose CD4(+) T lymphocyte counts had increased by >/=100 cells/microL t

140 Low lymphocyte count has been shown to be an independent pro

141 The immediate risk of an ADI for a given CD4 lymphocyte count has declined over time and is lower amo

142 d be used for diagnosis, and (3) whether any lymphocyte count has independent prognostic value after

143 ry OI prophylaxis among persons whose CD4+ T lymphocyte counts have increased in response to antiretr

144 ultivariate logistic regression model, nadir lymphocyte count, history of depression, and female sex,

145 cific studies at baseline should include CD4 lymphocyte count, HIV-1 RNA level, and gynecologic exami

146 herapy and level of immunodeficiency (CD4+ T lymphocyte count, human immunodeficiency virus [HIV] RNA

147 Lymphocyte counts, Ig levels, and anti-double-stranded D

148 Despite dramatic increases in CD4(+) lymphocyte counts, IL-2 did not enhance immunization res

149 Responders had a higher maximum lymphocyte count immediately after therapy compared with

150 A marked decrease in T- and B-lymphocyte counts immediately after transplant was follo

151 We assessed the prognostic value of total lymphocyte count, immune complex-dissociated p24 antigen

152 ciated with a markedly decreased circulating lymphocyte count in 9 of 10 trauma patients.

153 U.S.-born participants, but only with higher lymphocyte count in foreign-born participants.

154 CD3+ lymphocyte count in the peripheral blood was determined

155 vity for S1P1 efficiently reducing the blood lymphocyte count in the rat were identified.

156 gonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat.

157 ently and dose dependently reduced the blood lymphocyte count in the rat.

158 APH-2 levels were not correlated with lymphocyte count in vivo, consistent with the inability

159 inally, we mapped the phenotype of pulmonary lymphocyte counts in BALB x C57BL/6J F2 Cftr(tm1UNC) mic

160 White blood cell and lymphocyte counts in Dll4-overexpressing mice were reduc

161 ncy virus type 1 (HIV-1) RNA levels and CD4+ lymphocyte counts in HIV-infected patients improved afte

162 Despite higher plasma HIV levels and CD4 lymphocyte counts in infancy, HAART can result in timely

163 These compounds efficiently reduce blood lymphocyte counts in rats through 24 h after single dose

164 , as demonstrated by an increase in CD4(+) T-lymphocyte counts in recent clinical trials.

165 Despite significantly lower total T- and B-lymphocyte counts in SIV-infected sooty mangabeys than i

166 after cessation of natalizumab therapy, low lymphocyte counts in the CSF persisted.

167 pheral lymph nodes and moderate reduction in lymphocyte counts in the peripheral lymph nodes, despite

168 t trend for overall decrease in the absolute lymphocyte counts in TMG group (F=5.86, mixed model grou

169 d neutrophil numbers, associated with normal lymphocyte count, in peripheral blood and bone marrow, s

170 incidence rose steadily with decreasing CD4 lymphocyte counts; in contrast, BL incidence was lowest

171 ed virus suppression, and children whose CD4 lymphocyte counts increased >70 cells/microL by 20 weeks

172 During antiretroviral therapy, CD4 lymphocyte count increases are modest in some patients d

173 s: plasma HIV-1 RNA level (viral load), CD4+ lymphocyte count, initiation of antiretroviral therapy (

174 iated with reduced increases in the CD4(+) T lymphocyte count, irrespective of plasma HIV RNA levels.

175 ciency virus-infected patients when the CD4+ lymphocyte count is < or =200 cells/mm3.

176 T) is recommended when the absolute CD4(+) T lymphocyte count is <200 cells/mm(3), and it should be c

177 ulin therapy, based on peripheral blood CD3+ lymphocyte counts, is safe and associated with low acute

178 The day-30 lymphocyte count (LC30) was strongly associated with out

179 stent lymphopenia was defined as an absolute lymphocyte count less than 1.2 cells/muLx10(3) present o

180 ere similar in patients with baseline CD4(+) lymphocyte counts less than 0.010 x 10(9) cells/L.

181 articularly in those individuals with CD4(+) lymphocyte counts less than 50/mm(3).

182 Prolonged lymphopenia (absolute lymphocyte count < 1000 for >7 days) occurred only in ch

183 openia was seen in 60% of patients (absolute lymphocyte count < 800/microL) with a median of 101 days

184 Twenty-four patients (55%) had CD4(+) lymphocyte count </= 200/mm(3).

185 ll proportional hazards model, baseline CD4+ lymphocyte count <200, black race, other nonwhite race,

186 Disease progression was defined as CD4(+) lymphocyte count <200/microl or the presence of an AIDS

187 ssion, comparable with that of cutoff CD4(+) lymphocyte count <350 lymphocytes/mm(3) and HIV-1 RNA le

188 Cell-mediated immunodeficiency (CD4(+) lymphocyte count <500 cells/mm(3)) was significantly ass

189 sed among HIV-seropositive women with CD4(+) lymphocyte counts <500 cells/mm(3) and among women with

190 median CD3+CD4+, CD3+CD8+, CD19+, and CD56+ lymphocyte counts measured at a median followup of 11.8

191 omen: </= 0.65 vs >0.05 mg/dL, P = .004) and lymphocyte count (men: </= 1700 vs >1700/muL, P = .04; w

192 Nadir lymphocyte count, not nadir neutrophil count, was indepe

193 ed an inverse association between IE and CD4 lymphocyte count (odds ratio [OR] for 200-499 cells/mm(3

194 Absolute lymphocyte count of <200 cells/mm(3) was associated with

195 Initiating HAART with a CD4+ lymphocyte count of <200 cells/mm3 was associated with a

196 At baseline, patients had a median CD4(+) lymphocyte count of 0.015 x 10(9) cell/L, median plasma

197 values of 50 copies/mL or fewer and a CD4 T-lymphocyte count of 100 cells/mL or greater or patients

198 Eight patients with median lymphocyte count of 35.9 x 10(9)/L and median serum beta

199 ts with untreated HIV infection with a CD4 T-lymphocyte count of 500 cells/mL or greater.

200 bility of survival (P = .0032), and baseline lymphocyte count of at least 1,000/muL and response (CR/

201 activities of daily living status, absolute lymphocyte count of less than 800/microL (0.8 x 10(9)/L)

202 HAART should be initiated at CD4+ lymphocyte counts of >200 cells/mm3.

203 gressed faster than those with baseline CD4+ lymphocyte counts of >350 cells/mm3 (P=.01).

204 ble virologic suppression with baseline CD4+ lymphocyte counts of >350 cells/mm3 (P=.40).

205 s (VCs) (<5,000 HIV-1 RNA copies/ml and CD4+ lymphocyte counts of >400 cells/mul) capable of soluble

206 was 52.2% when their male partners had CD4+ lymphocyte counts of <200 cells/microL, 45.9% in women w

207 ologic suppression, those with baseline CD4+ lymphocyte counts of <200 cells/mm3 tended to progress f

208 rogress faster than those with baseline CD4+ lymphocyte counts of 201-350 cells/mm3 (P=.09) and progr

209 progression between those with baseline CD4+ lymphocyte counts of 201-350 cells/mm3 and those with du

210 to 55 HIV-1-infected individuals with CD4+ T lymphocyte counts of 50-500 cells/microL.

211 as provided if participants had CD4-positive lymphocyte counts of fewer than 200 cells per muL.

212 ed with advanced extranodal disease and CD4+ lymphocyte counts of less than 200/mm3.

213 nfected individuals with a history of CD4+ T-lymphocyte counts of less than 50/microL, but with curre

214 bstantial differences were found in absolute lymphocyte count or multiple immune cell subsets, includ

215 e no statistically significant reductions in lymphocyte count or serum immunoglobulin, anticardiolipi

216 d-maternal ratios were independent of CD4(+) lymphocyte counts or HIV-1 viral load.

217 dicated the need to change the threshold CD4 lymphocyte counts or HIV-RNA levels for initiation of th

218 l count (OR, 0.88; P = .049) and lower total lymphocyte count (OR, 0.76; P = .050) were associated wi

219 no correlation between cCD20 level and age, lymphocyte count, or white blood cell count.

220 of nausea and vomiting, decline in absolute lymphocyte count over several hours or days after exposu

221 P < .001); and larger CRAE with lower CD4+ T lymphocyte count (P = .04).

222 ogic outcome (P < 0.001) and increase in CD4 lymphocyte count (P = 0.006).

223 llomavirus infection (p=0.0013), lower CD4 T lymphocyte count (p = 0.0395), and history of frequent i

224 ow hemoglobin (p = 0.11), and CD4-positive T-lymphocyte count (p = 0.04).

225 ortened survival was associated with low CD4 lymphocyte count (P<.0001), no ART (P<.0001), and crypto

226 all assay-alternatives to CD4 and RNA, total lymphocyte count (p<0.0001) and serum albumin (p=0.0107)

227 3), serious infection (P=0.0.018), and lower lymphocyte count (P=0.001) associated with increased mor

228 01) and neutrophil (P < 0.01) counts and low lymphocyte counts (P < 0.01).

229 erval, 0.0-4.5%) among those with higher CD4 lymphocyte counts (p < 0.01).

230 One week after transfer, lymphocyte counts peaked (median of 14.3 x 10(3) cells//

231 Naive lymphocyte counts peaked around 1 year, whereas most mem

232 count; high white blood cell, monocyte, and lymphocyte counts; presence of circulating immature myel

233 VB analysis did not correlate with the lymphocyte count prior to lymphocytotoxic therapy; howev

234 , heart failure, diabetes mellitus, relative lymphocyte count, prothrombin time, peripheral artery di

235 correlated significantly with current CD4+ T-lymphocyte count (r = - 0.344, P = 0.022).

236 ationship between level of infection and CD4 lymphocyte count (R = -0.73; P < 0.001).

237 24 antigen level correlated with both CD4(+) lymphocyte count (r=-0.34; P<.0001) and HIV-1 RNA level

238 nant women according to age, baseline CD4(+) lymphocyte count, receipt of HAART, and date of cohort e

239 Lymphocyte counts recovered to LLN after a single course

240 e donor chimerism (P = .04) and faster total lymphocyte count recovery (P = .04) without any statisti

241 sis are associated with the magnitude of CD4 lymphocyte count recovery during antiretroviral therapy.

242 Absolute lymphocyte count remained below preoperative level for 1

243 uring the peak of viremia, the milk CD4(+) T lymphocyte counts remained unchanged, despite active vir

244 Despite absolute lymphocyte counts remaining between 500-1000/mm(3) , his

245 subgroups based on current and nadir CD4+ T-lymphocyte counts (severely immunosuppressed, immune rec

246 ristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved

247 Lower circulating leukocyte, neutrophil, and lymphocyte counts show the anti-inflammatory effects of

248 95% CI, 0.01-4.8; P = .35), intraepithelial lymphocyte counts (standardized mean difference, 0.21; 9

249 iovascular risk factors, HIV viral load, CD4 lymphocyte count, statin use, antihypertensive use, and

250 the incidence of ADIs overall and within CD4 lymphocyte count strata, the relationship with treatment

251 tients not on this treatment within each CD4 lymphocyte count strata.

252 e more likely to present with lower CD4(+) T-lymphocyte counts than MSM who do not attend church.

253 accompanied by a transient rise in absolute lymphocyte count that is asymptomatic and probably the r

254 Patients in groups 1 and 2 had CD4+ T-lymphocyte counts that were similar to those in patients

255 The serum absolute lymphocyte count, the presence of tumor-infiltrating den

256 odeficiency virus type 1 (HIV-1) load, total lymphocyte count (TLC), body mass index (BMI), and hemog

257 participants with marked lymphopenia (total lymphocyte count [TLC] </=1200 cells/muL).

258 Two had transient decrease in lymphocyte count to normal, whereas in 5, disease progre

259 ne metagene expression values and histologic lymphocyte counts to quantify immune infiltration and as

260 Geometric mean recovery time (GMRT) of total lymphocyte counts to the lower limit of the normal range

261 The pre-ART viral load and CD4+ lymphocyte count trajectories were also comparable betwe

262 t reduction of white blood cell and absolute lymphocyte count up to 1 year posttransplant.

263 art HIV diagnostic technologies for CD4(+) T lymphocyte count, viral load measurement, and drug resis

264 onal Prognostic Index scores; the median CD4 lymphocyte count was 112/mm(3) (range, 19/mm(3) to 791/m

265 retroviral therapy (ART), and the median CD4 lymphocyte count was 131 cells/microL.

266 The median entry CD4(+) lymphocyte count was 20 cells/mm(3) (range, 0 to 358).

267 The mean (SD) age was 35 (6.9) years, CD4 T-lymphocyte count was 236 (139) and log10 plasma HIV RNA

268 l load of <400 copies/mL), and median CD4+ T-lymphocyte count was 459 cells/mm(3) (interquartile rang

269 d of <400 copies/mL, and the median CD4(+) T-lymphocyte count was 471 cells/microL.

270 Twenty-four hours post-CLP, the lymphocyte count was higher in the P-DIE than in the P-L

271 The median CD4 lymphocyte count was highest with pathogen-free diarrhea

272 In this group, CD4+ T-lymphocyte count was low, despite a significantly lower

273 0.7+/-0.6 vs. 2.1+/-1.0, P=0.0004); however, lymphocyte count was recovered and was back to reference

274 The decline in CD4 lymphocyte counts was strongly associated with initial H

275 cific T cell responses, in addition to total lymphocyte counts, was also observed.

276 a T-cell leukemia showing rapidly rising PB lymphocyte counts, was the only tumor type expressing th

277 < .001), and lower CD4 cell count and total lymphocyte count were associated with bacteremic dissemi

278 88 through 1998, the viral load and the CD4+ lymphocyte count were measured approximately every six m

279 Prolactin levels and absolute lymphocyte count were measured on days 1, 3, 7, 14, and

280 ral load and sustained decreases in CD4(+) T lymphocyte count were observed, especially in subjects w

281 White blood cell and absolute lymphocyte count were significantly lower in alemtuzumab

282 HIV-1 infection and low CD4(+) lymphocyte count were strongly associated with HPV infec

283 Mean (SD) baseline and nadir CD4+ lymphocyte counts were 553(217) and 177(117) cells/micro

284 Low lymphocyte counts were associated with wide QRS duration

285 CSF lymphocyte counts were explored in 151 MS patients recru

286 The recovery of peripheral leukocyte and lymphocyte counts were faster and more complete in mice

287 Throughout the 100 weeks, CD4+ lymphocyte counts were higher in the OZ1 group.

288 Current and nadir (lowest previous) CD4+ T-lymphocyte counts were identified for each subject.

289 marrow tumor only occurred if circulating B-lymphocyte counts were persistently less than 0.001 x 10

290 Circulating lymphocyte counts were reduced in 18 of 26 patients with

291 Lymphocyte counts were retrospectively analyzed in 1,377

292 tastases, and serum hemoglobin, albumin, and lymphocyte counts were significant for predicting surviv

293 Total lymphocyte counts were significantly lower in the RIT gr

294 Submucosal mast cell, neutrophil, and lymphocyte counts were similar in both groups.

295 A higher lymphocyte count when ribavirin therapy was initiated wa

296 eater virologic suppression and higher CD4 T-lymphocyte counts when managed by a multidisciplinary te

297 ased on the viral load, rather than the CD4+ lymphocyte count, will lead to differences in eligibilit

298 toward progressive modest increases in CD4+ lymphocyte counts with GM-CSF treatment at 16 weeks (med

299 istribution phenomenon, we correlated serial lymphocyte counts with volumetric changes in lymph node

300 was seen after stratification by latest CD4 lymphocyte count within each year (< or = 50, 51-200, an